We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us

Download Mobile App




New Technique Successfully Delivers RNA Drugs into Brain

By LabMedica International staff writers
Posted on 06 Apr 2011
The blood-brain barrier has been a key complication to delivering gene-silencing or RNA-interference (RNAi) drugs into the brain to treat disorders such as muscular dystrophy, Alzheimer's disease, Parkinson's disease (AD), and other neurologic disorders. More...
However, British researchers have discovered one possible way to penetrate this barrier and deliver RNAi treatments into brain cells.

In a mouse study, investigators from the University of Oxford (UK) revealed that engineered versions of exosomes, which are naturally occurring carriers of RNA molecules and other proteins among cells, were able to deliver small interfering RNAs (siRNA) to specific sites in the brain and turn off an AD gene target called BACE1. The study's findings were published online on March 20, 2011, in the journal Nature Biotechnology.

The team has successfully turned off a gene implicated in AD in the brains of mice by exploiting exosomes --tiny particles naturally released by cells. The exosomes, injected into the blood, are able to deliver a drug across the typically impermeable blood-brain barrier to the brain where it is needed.

Although this is an important and promising finding, there are a number of steps to be taken before this new form of drug delivery can be tested in humans in the clinic. "These are dramatic and exciting results. It's the first time new ‘biological' medicines have been delivered effectively across the blood-brain-barrier to the brain," said Dr. Matthew Wood of the department of physiology, anatomy, and genetics at the University of Oxford, who led the study. "This is the first time this natural system has been exploited for drug delivery," remarked Dr. Wood.

Dr. Matthew Wood Novel drugs based on antibodies, peptides, or more recently, RNA molecules have been developed on many instances to target specific regions of disease pathways. While these have shown good results in the laboratory, too frequently it has proved difficult to get the drugs to the correct areas of the body to see any effect in humans.

Currently, delivering any such type of therapy to the brain would have to involve neurosurgery. Nothing delivered intravenously would be able to cross from the blood into the brain. "The major barrier for these drugs is delivery," noted Dr. Wood. "This problem becomes even greater when you want to reach the brain. The blood-brain barrier--which stops most things in the blood stream from crossing to our brains--is much too great an obstacle."

The Oxford University researchers set out to modify naturally occurring exosomes to deliver a gene therapy. They used an RNA sequence that switches off a gene that is implicated in Alzheimer's disease.

To be able to make the application succeed, the researchers would need to be able to load the exosomes with the RNA, the drug. But they would also need to be able to target the appropriate tissues in the body. First of all, they produced and purified exosomes from mouse cells. They then developed and patented new techniques to both insert RNA molecules into the exosomes and add protein elements into the exosome coat that would target nerve cells.

The exosomes, injected intravenously into mice, crossed the blood-brain barrier and ended up in the brain. Once there, the RNA was able to switch off a gene implicated in the accumulation of malformed protein in AD. This resulted in a 60% decrease in the brain of the problem enzyme encoded by the gene.

"We've shown that a natural system could be exploited to deliver drugs across the blood-brain barrier," explained Dr. Wood. "We believe we can use this same technology for Alzheimer's, motor neuron disease, Parkinson's and Huntington's. All we need is a different RNA each time. The next steps are to test the exosomes in a mouse model of Alzheimer's disease to see if it makes a difference to disease progression."

Dr. Wood also noted that other steps would be needed before exosomes could be evaluated in humans, including safety tests and scaling up the procedures. "Many of these diseases have not been possible to treat in the last 50 years using standard drugs. New drugs have been developed based on complex biological molecules--antibodies, peptides, and RNA--but all require new ways of delivering the drugs. These natural nanoparticles would be administered intravenously or perhaps even orally, and would still reach the brain."

Related Links:

University of Oxford



Gold Member
Hematology Analyzer
Medonic M32B
Portable Electronic Pipette
Mini 96
Gold Member
Automatic Hematology Analyzer
DH-800 Series
6 Part Hematology Analyzer with RET + IPF
Mispa HX 88
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Hematology

view channel
Image: New evidence shows viscoelastic testing can improve assessment of blood clotting during postpartum hemorrhage (Photo courtesy of 123RF)

Viscoelastic Testing Could Improve Treatment of Maternal Hemorrhage

Postpartum hemorrhage, severe bleeding after childbirth, remains one of the leading causes of maternal mortality worldwide, yet many of these deaths are preventable. Standard care can be hindered by delays... Read more

Immunology

view channel
Image: The CloneSeq-SV approach can allow researchers to study how cells within high-grade serous ovarian cancer change over time (Photo courtesy of MSK)

Blood Test Tracks Treatment Resistance in High-Grade Serous Ovarian Cancer

High-grade serous ovarian cancer (HGSOC) is often diagnosed at an advanced stage because it spreads microscopically throughout the abdomen, and although initial surgery and chemotherapy can work, most... Read more

Pathology

view channel
Image: The new system allows surgeons to identify genotyping of brain tumors and determine optimal resection margins during surgery (Photo courtesy of Nagoya University)

New Technique Detects Genetic Mutations in Brain Tumors During Surgery within 25 Minutes

Determining the genetic profile of brain tumors during surgery is crucial for improving patient outcomes, but conventional analysis methods can take up to two days, delaying critical decisions.... Read more

Industry

view channel
Image: The collaboration aims to improve access to Hb variant testing with the Gazelle POC diagnostic platform (Photo courtesy of Hemex Health)

Terumo BCT and Hemex Health Collaborate to Improve Access to Testing for Hemoglobin Disorders

Millions of people worldwide living with sickle cell disease and other hemoglobin disorders experience delayed diagnosis and limited access to effective care, particularly in regions where testing is scarce.... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.